Pharma Deals Review, Vol 2004, No 54 (2004)

Font Size:  Small  Medium  Large

Nippon Shinyaku Out-Licenses Cancer and Stroke Drugs

Business Review Editor

Abstract


Nippon Shinyaku entered into two major licensing agreements with IVAX and PAION. The first deal granted IVAX the exclusive worldwide development and marketing rights to HMN-214. In the second deal, PAION acquired the exclusive development and marketing rights to a neuroprotective drug Enecadin.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.